title: Cysteine regulates expression of cysteine dioxygenase and gamma-glutamylcysteine synthetase in cultured rat hepatocytes.
abstract: Rat hepatocytes cultured for 3 days in basal medium expressed low levels of cysteine dioxygenase (CDO) and high levels of gamma-glutamylcysteine synthetase (GCS). When the medium was supplemented with 2 mmol/l methionine or cysteine, CDO activity and CDO protein increased by >10-fold and CDO mRNA increased by 1.5- or 3.2-fold. In contrast, GCS activity decreased to 51 or 29% of basal, GCS heavy subunit (GCS-HS) protein decreased to 89 or 58% of basal, and GCS mRNA decreased to 79 or 37% of basal for methionine or cysteine supplementation, respectively. Supplementation with cysteine consistently yielded responses of greater magnitude than did supplementation with an equimolar amount of methionine. Addition of propargylglycine to inhibit cystathionine gamma-lyase activity and, hence, cysteine formation from methionine prevented the effects of methionine, but not those of cysteine, on CDO and GCS expression. Addition of buthionine sulfoximine to inhibit GCS, and thus block glutathione synthesis from cysteine, did not alter the ability of methionine or cysteine to increase CDO. GSH concentration was not correlated with changes in either CDO or GCS-HS expression. The effectiveness of cysteine was equivalent to or greater than that of its precursors (S-adenosylmethionine, cystathionine, homocysteine) or metabolites (taurine, sulfate). Taken together, these results suggest that cysteine itself is an important cellular signal for upregulation of CDO and downregulation of GCS.
authors: Division of Nutritional Sciences, Cornell University, Ithaca, New York 14853, USA.
authors: Y H
authors: YH
authors: Kwon
authors: M H
authors: MH
authors: Stipanuk
mesh_terms: D000480:Alkynes / Q000494:pharmacology; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D002478:Cells, Cultured; D003545:Cysteine / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D050558:Cysteine Dioxygenase; D049308:Dioxygenases; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005721:Glutamate-Cysteine Ligase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D022781:Hepatocytes / Q000187:drug effects* / Q000201:enzymology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D008715:Methionine / Q000378:metabolism / Q000494:pharmacology; D010105:Oxygenases / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000480:Alkynes; D000963:Antimetabolites; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D019328:Buthionine Sulfoximine; C009055:propargylglycine; D008715:Methionine; D010105:Oxygenases; D049308:Dioxygenases; D050558:Cysteine Dioxygenase; D005721:Glutamate-Cysteine Ligase; D003545:Cysteine; D005998:Glycine